{{expert|time=2015-08-25T13:53:19+00:00}}
{{Infobox gene}}
'''钠-葡萄糖协同转运蛋白2'''（SGLT2）是由SLC5A2（溶質載體家族5成員2）[[基因|基因]]編碼的[[蛋白質|蛋白質]]<ref name="pmid8244402">{{cite journal | vauthors = Wells RG, Mohandas TK, Hediger MA | title = Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere | journal = Genomics | volume = 17 | issue = 3 | pages = 787–9 | date = Sep 1993 | pmid = 8244402 | doi = 10.1006/geno.1993.1411 }}</ref>。

== 功能 ==
SGLT2屬於[[鈉依賴型葡萄糖共同運輸蛋白|鈉依賴型葡萄糖共同運輸蛋白]]，是和鈉濃度有關的[[葡萄糖|葡萄糖]]共同運輸蛋白。SGLT2是[[腎臟|腎臟]]內主要协同转运蛋白葡萄糖{{le|重吸收|reabsorption}}的主要协同转运蛋白<ref name="entrez">{{cite web | title = Entrez Gene: solute carrier family 5 (sodium/glucose cotransporter)| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=6524| accessdate = }}</ref>。

大部份SGLT2都是位於近端腎小管細胞中S1段和S2段的刷狀薄膜，負責將腎臟中90%的葡萄糖重新吸收，繼而促進葡萄糖穿過腎臟細胞，再吸收到血液中<ref>Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3):671-81.</ref><ref> Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications; Diabetic Med. 2010;27:136–142</ref>。

== 作用==
對健康人士而言，幾乎所有已過濾的葡萄糖都會被SGLTs重新吸收到近端腎小管 (約90％被SGLT2吸收，其餘10％被SGLT1吸收)，然後返回到血液中。當血糖低於某一水平(即是腎糖水平)，腎臟會吸收葡萄糖，因此尿液中幾乎不會含有糖份<ref>Abdul-Ghani et al. SGLT2 inhibition and Type 2 Diabetes. Endocrine Reviews, August 2011, 32(4):515–531 7. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3):671-81.</ref><ref>Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3):671-81.</ref>。

== SGLT2和二型糖尿病 ==
至於糖尿病患者，其血糖水平已超過一般的腎糖水平，令葡萄糖必須通過尿液排出體外<ref>Abdul-Ghani et al. SGLT2 inhibition and Type 2 Diabetes. Endocrine Reviews, August 2011, 32(4):515–531 7. Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009; 25(3):671-81.</ref>。在二型糖尿病患者體內， SGLT2有可能過於活躍，導致腎臟重新吸收過多葡萄糖<ref>Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications; Diabetic Med. 2010;27:136–142</ref><ref>Rahmoune et.al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non–insulin-dependent diabetes; Diabetes, Vol. 54, December 2005: 3427-34</ref>。

== 抑制SGLT2 ==
抑制SGLT2可減少近端腎小管重新吸收葡萄糖至血液的份量，增加尿糖排泄量、熱量流失和滲透性利尿。因此，抑制SGLT2對血糖、體重和血壓，均有改善作用<ref> Rosenstock J, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with Type 2 Diabetes. Diabetes Care. 2012. </ref><ref>List JF, et al. Sodium-glucose cotransport inhibition with dapagliflozin in Type 2 Diabetes. Diabetes Care 2009; 32:650-7.</ref><ref>Wilding JPH, et al. A study of dapagliflozin in patients with Type 2 Diabetes receiving high doses of insulin plus insulin sensitizers. Diabetes Care. 2009; 32:1656-62.</ref><ref>Zhang L, et al. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes, Obesity and Metabolism. 2010; 12:510-6. </ref>。

=== 抑制SGLT2在糖尿病及相關管理中的重要角色 ===
要妥善管理二型糖尿病，是相當複雜及具挑戰性的。雖然二型糖尿病患者可使用各種治療方法降低血糖，但不少個案採用了這些方法後，仍未必能達致理想的血糖目標。至於療效未如理想的成因，多是因為在治療過程中，出現了副作用，如體重增加、低血糖和胃腸道不適等，因而拖延了治療進度<ref>Nair, S. and Wilding, J. P. H. Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus. J Clin Endocrinol Metab. 2010. 95(1):34–42.</ref>。

SGLT2抑制劑能直接針對葡萄糖，且毋需依賴β細胞功能和胰島素抗性機制<ref>Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: A novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocrine Practice. 2008;14:782-90</ref><ref> Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009 Feb; 11(2):79-88.</ref>。

目前，醫學界正就SGLT2抑制劑的抑制機制進行臨床研究，期望找出此機制對控制糖尿病患者的血糖、體重、血壓、β細胞功能和胰島素抵抗程度等的成效。此外，醫學界亦正在研究SGLT2抑制劑導致低血糖症、尿道和生殖器感染的風險。

醫學界期望，SGLT2抑製劑可成為治療二型糖尿病(T2D)的另一個重要臨床方案。

=== 認識抑製SGLT2的研發過程 <ref>Ehrenkranz, J. R. L. et al. Phlorizin: a review. Diabetes Metab Res Rev. 2005; 21: 31–38.</ref>===
* 早於在1835年，根皮苷複合物是由法國化學家發現可從蘋果樹的根皮中分離出來，後來被研製成SGLT1抑製劑和SGLT2抑製劑。
* 動物研究顯示，根皮苷能誘導尿糖排泄，使空腹血糖持續正常水平，和避免餐後高血糖症。
* SGLT2抑製劑的效用則與根皮苷相類似，但抑製劑已被合成為更有效和更選擇性針對SGLT2，因此治療效果會更為顯著。

==參考資料==

[[Category:转运蛋白|Category:转运蛋白]]